Can a daily pill keep the weight off after stopping injectables?

NCT ID NCT06584916

Completed Disease control Sponsor: Eli Lilly and Company Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This phase 3 trial tests whether a daily oral drug called orforglipron can help people with obesity or overweight maintain weight loss they achieved with injectable tirzepatide or semaglutide. About 376 participants who completed a prior weight-loss study will receive orforglipron or a placebo. The main goal is to see how well they keep the weight off over time.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: orforglipron
What this could lead to: If it works, this could offer a daily pill to help people keep off weight they lost with injectable weight-loss drugs.
What could go wrong: This is a maintenance study, not a new weight-loss treatment. It is still experimental, and results may not apply to everyone. Side effects are possible.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Body Weight Changes Obesity obesity disorder Overweight Weight Loss

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

OBESITY OVERWEIGHT

Contacts and locations

Locations

Alliance for Multispecialty Research, LLC

Norman, Oklahoma, 73069, United States
Arcturus Healthcare , PLC, Troy Internal Medicine Research Division

Troy, Michigan, 48098, United States
Biopharma Informatic, LLC

Houston, Texas, 77043, United States
Cahaba Research

Birmingham, Alabama, 35242, United States
Cahaba Research - Pelham

Pelham, Alabama, 35124, United States
Encompass Clinical Research

Spring Valley, California, 91978, United States
Iowa Diabetes and Endocrinology Research Center

West Des Moines, Iowa, 50265, United States
L-MARC Research Center

Louisville, Kentucky, 40213, United States
Lillestol Research

Fargo, North Dakota, 58104, United States
New Horizon Research Center

Miami, Florida, 33165, United States
North Texas Endocrine Center

Dallas, Texas, 75231, United States
Palm Research Center Sunset

Las Vegas, Nevada, 89148, United States
Palm Research Center Tenaya

Las Vegas, Nevada, 89128, United States
PharmQuest Life Sciences, LLC

Greensboro, North Carolina, 27408, United States
PlanIt Research, PLLC

Houston, Texas, 77079, United States
Prime Health and Wellness/SKYCRNG

Fayette, Mississippi, 39069, United States
Puerto Rico Medical Research

Ponce, 00717, Puerto Rico
Rocky Mountain Clinical Research

Idaho Falls, Idaho, 83404, United States
Rophe Adult and Pediatric Medicine/SKYCRNG

Union City, Georgia, 30291, United States
Southern California Dermatology, Inc.

Santa Ana, California, 92701, United States
Southern Endocrinology Associates

Mesquite, Texas, 75149, United States
StudyMetrix Research

City of Saint Peters, Missouri, 63303, United States
The University of Texas Health Science Center at Houston

Bellaire, Texas, 77401, United States
Tribe Clinical Research, LLC

Greenville, South Carolina, 29607, United States
University Clinical Investigators, Inc.

Tustin, California, 92780, United States
Velocity Clinical Research, Dallas

Dallas, Texas, 75230, United States
WR-Clinsearch, LLC

Chattanooga, Tennessee, 37421, United States
Weill Cornell Medical College

New York, New York, 10021, United States
Wellness clinical Research Vega Baja

Vega Baja, 00694, Puerto Rico

More trials for these conditions

Other studies related to the condition(s) this trial covers.